



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/060,754	01/30/2002	Jeffry B. Skiba	125827-1000	8210
7590 03/23/2006				
Gardere Wynne Sewell LLP 3000 Thanksgiving Tower Suite 3000 1601 Elm Street Dallas, TX 75201-4767		EXAMINER ANDERSON, CATHARINE L		
		ART UNIT 3761 PAPER NUMBER		

DATE MAILED: 03/23/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/060,754

Applicant(s)

SKIBA ET AL.

Examiner

C. Lynne Anderson

Art Unit

3761

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 19 December 2005.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-6,8,10,11,15,17-22 and 24-31 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-6,8,10,11,15,17-22 and 24-31 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- ☒ Notice of References Cited (PTO-892)
- ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____.
- ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____.
- ☐ Notice of Informal Patent Application (PTO-152)
- ☐ Other: _____.

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 19 December 2005 has been entered.

Allowable Subject Matter

The indicated allowability of claim 16 is withdrawn in view of the newly discovered reference(s) to Hewitt et al. (5,216,759). Rejections based on the newly cited reference(s) follow.

Response to Arguments

Applicant's arguments with respect to claims 1-15 and 17-31 have been considered but are moot in view of the new ground(s) of rejection.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Art Unit: 3761

Claims 1-6, 10-11, 15, 17, 19-22, and 25-31 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kang (5,807,357) in view of Hewitt et al. (5,216,759).

Kang discloses all aspects of the claimed invention with the exception of the conduits being flexible. Kang discloses an apparatus for delivering medicine to tissues, as shown in figure 2, comprising a mask 10 to be worn around the eyes, the mask 10 comprising fog outlets (shown as holes in figure 3, but not numbered). An atomizer 20 atomizes medicine 90 into a fog to be discharged from the fog outlets.

Hewitt discloses goggles of a similar construction to the mask of Kang, and teaches constructing the mask using a flexible material in order to allow the mask to conform to the wearer, as disclosed in column 3, lines 47-52. A mask that conforms to the face of the wearer provides a secure fit, which would ensure the fog discharged into the mask of Kang would not escape the mask, and therefore the mask of Kang would be more effective in delivering the fog to the eyes of the wearer. If the mask of Kang is constructed from a flexible material, the conduits, which comprise part of the mask, would also be flexible.

It would therefore be obvious to one of ordinary skill in the art at the time of invention to construct the mask of Kang out of a flexible material, as taught by Hewitt, to allow the mask to conform to the wearer and provide a secure fit.

With respect to claim 2, the atomizer 20 comprises an ultrasonic atomizer, as disclosed in column 2, lines 29-32.

Art Unit: 3761

With respect to claim 3, the atomizer 20 comprises a nozzle 11, as shown in figure 3.

With respect to claim 4, the atomizer 20 is a nebulizer, as disclosed in column 1, line 54.

With respect to claim 5, Kang discloses all aspects of the claimed invention with the exception of the atomizer being a stirrer. Stirrers are well-known in the art as being suitable atomizers comparable to nebulizers. It would therefore be obvious to one of ordinary skill in the art at the time of invention to make the apparatus of Kang with a stirrer.

With respect to claim 6, the atomizer 20 comprises a medication chamber 71, as shown in figure 2.

With respect to claims 10-11 and 26-27, Kang discloses all aspects of the claimed invention with the exception of the propellant source comprising a compressed gas canister or a pump. Kang discloses the propellant source is a fan, as described in column 2, lines 33-35. It is well-known in the art that a compressed gas canister or pump perform a comparable function to a fan, and it would therefore be obvious to one of ordinary skill in the art at the time of invention to construct the apparatus of Kang with a compressed gas canister or a pump.

With respect to claim 15, the apparatus comprises a mask 10 having a transparent face mask 12 to be worn around the eyes, fog outlets (shown as holes in figure 3, but not numbered), an atomizer 20 to atomize medicine 90 into

Art Unit: 3761

a fog, a medication chamber 71, a power supply 40, a propellant source 30, and a conduit 11.

With respect to claim 17, the power supply 40 comprises a battery, as disclosed in column 1, line 60.

With respect to claims 19 and 20, the method of administering medications to the eyes by nebulizing a medication to form a fog and contacting the fog with the eyes is disclosed in column 2, lines 27-36.

With respect to claim 21, the apparatus comprises a device 10 comprising fog outlets (shown as holes in figure 3, but not numbered), and an atomizer 20 in fluid communication with the fog outlets.

With respect to claim 22, the atomizer 20 is a nebulizer, as disclosed in column 1, line 54.

With respect to claim 25, a propellant source 30 is in fluid communication with the atomizer 20.

With respect to claim 28, a power supply 40 is connected to the atomizer 20.

With respect to claim 29, the power supply 40 comprises batteries, as disclosed in column 1, line 60.

With respect to claims 30 and 31, Kang discloses a method of providing the mask described above and atomizing fluid into a fog, as disclosed in column 2, lines 27-36.

Art Unit: 3761

Claims 8, 18, and 24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kang (5,807,357) in view of Hewitt et al. (5,216,759) as applied to claims 1, 15, and 21 above, and further in view of Dykstra et al. (5,935,982).

Kang, as modified by Hewitt, discloses all aspects of the claimed invention but remains silent as to the size of the liquid droplets of the fog. Dykstra discloses administering a medicine to the eyes, the medicine being in the form of liquid droplets having a size of less than 5 microns, as described in column 12, lines 13-15 and 36-37. It would therefore be obvious to one of ordinary skill in the art at the time of invention to make the droplets of Kang less than 5 microns, since Kang teaches less than 5 microns as a suitable size for medicine being delivered to the eyes.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to C. Lynne Anderson whose telephone number is (571) 272-4932. The examiner can normally be reached on Monday through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Tanya Zalukaeva can be reached on (571) 272-1115. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 3761

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

CMA
cla
March 17, 2006

TATYANA ZALUKAEVA
SUPERVISORY PRIMARY EXAMINER

